Common cholesterol drug prevents, reverses MS symptoms in mice

Lipitor (atorvastatin), the most frequently used cholesterol lowering agent in the world, also has the ability to influence the immune system and proved effective in reversing paralysis in a mouse model of multiple sclerosis. Dr. Sawsan Youssef, a postdoctoral fellow in the laboratory of Dr. Lawrence Steinman, Stanford University, reported the study on April 23 at the Experimental Biology 2002 meeting in New Orleans.

Multiple sclerosis is caused by the immune system attacking the bodys own central nervous system, breaking down the myelin that sheathes and protects CNS nerves, impairing the bodys ability to move normally, and eventually causing paralysis. The T lymphocytes of the mice with which the research team worked are sensitized to brain antigens so that they produce an over-abundance of cytokines, pro-inflammatory chemicals that inflame the CNS, causing demylination of nerve sheaths through the same mechanism and in the same manner as happens in human multiple sclerosis. As in humans with MS, this mouse condition (called experimental autoimmune encephalomyelitis or EAE) can occur in either an acute or relapsing form. The researchers found that oral treatment with lipitor could prevent both the acute and relapsing form of the multiple sclerosis-like disease in the mice, and could also reverse symptoms in mice with the ongoing chronic relapsing form of the disease. Compared with control mice, the mice treated with lipitor had much less CNS inflammation. A close comparison of the lymphocytes of lipitor-treated and control-treated mice showed that lipitor prevented the induction of the pro-inflammatory cytokines and induced secretion of anti-inflammatory cytokines.

Dr. Youssef says that the mechanism by which lipitor affected the immune system suggests that it and other statin medications may have implications for the treatment of multiple sclerosis and other inflammatory autoimmune diseases including insulin-dependent diabetes mellitus

Contact: Sarah Goodwin
Federation of American Societies for Experimental Biology

Page: 1 2

Related biology news :

1. Common cold virus can cause polio in mice when injected into muscles
2. Common call for action on European Research Council (ERC)
3. Common therapy for HIV associated with cervical abnormality regression
4. Common chemicals morphing into potential toxins in Arctic
5. Common worm provides insights into salmonella virulence
6. Common virus may contribute to uncommon bone disease in children
7. Common airborne substance makes asthmatics more sensitive to house dust mites: study
8. Common genetic damages in non-dividing cells lead to the creation of mutant proteins
9. Common nutrients fed to pregnant mice altered their offsprings coat color
10. Common treatment for depression is safe and effective for Alzheimers patients
11. Common gene variant increases risk of atherosclerosis

Post Your Comments:

(Date:11/14/2019)... (PRWEB) , ... November 13, 2019 , ... Personalized ... the first patients in an FDA approved clinical trial for stem cell treatment ... the formation of the company as a subsidiary of VetStem Biopharma. , In July ...
(Date:11/12/2019)... ... 12, 2019 , ... The Arnold and Mabel Beckman Foundation ... institutions for its Instrumentation Grant for Advanced Light-Sheet Microscopy and Data Science ... for the acquisition of instrumentation, development and maintenance; support for data science collaborations ...
(Date:11/9/2019)... ... November 08, 2019 , ... StageBio ... histology, pathology, biomarker development, and archiving services for the biopharmaceutical, medical device ... Histo-Scientific Research Laboratories (HSRL), Vet Path Services (VPS) and Tox Path Specialists ...
Breaking Biology News(10 mins):
(Date:11/5/2019)... , ... November 04, 2019 ... ... of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene ... cell line development technology, GPEx® Boost. The technology enhances Catalent’s proven GPEx ...
(Date:11/2/2019)... , ... October 31, 2019 , ... ... Adaptive Biotechnologies in a live webinar on Friday, November 15, ... immuno-oncology. , Immunosequencing, the science of profiling T-cell receptors (TCRs) and B-cell ...
(Date:10/29/2019)... ... 28, 2019 , ... CaroGen Corporation , a biotechnology company, today announced ... Professor Jack R Wands, MD, of Brown University , Dr. Steve Projan, ... Mor, MD, PhD, of Wayne State University, formerly a professor at Yale University School ...
(Date:10/22/2019)... ... ... nQ Medical, Inc. of Cambridge, MA, was recognized in the top 5 ... at a showcase event yesterday in Los Angeles. nQ competed against 3,500 early-stage U.S. ... near-term growth projections to be named one of the most fundable companies in America. ...
Breaking Biology Technology:
Cached News: